Ark Therapeutics Group plc announced today that its novel gene-based drug targeting platform technology, Scavidin(R) has been shown to be highly effective in stopping tumour development in two cancer treatment models, using low doses of existing anti-cancer agents which would be sub-therapeutic if administered conventionally. Scavidin(R) was used to target and concentrate intravenous doses of as little as one-tenth the conventional levels of the radioisotope Yttrium(90) in one model, and the chemotherapy drug paclitaxel in another, to tumours growing under the skin. The results indicate a wide utility for this leading edge technology in very large markets.
